• Home
  • Measles Oncolytic Virus as an Immunotherapy for Recurrent/Refractory Pediatric Medulloblastoma and Atypical Teratoid/Rhabdoid Tumor: Results from PNOC005.

Measles Oncolytic Virus as an Immunotherapy for Recurrent/Refractory Pediatric Medulloblastoma and Atypical Teratoid/Rhabdoid Tumor: Results from PNOC005.

Author List
Yu B, Kline C, Hoare O, Jung J, Knowles T, Ranavaya A, Minturn J, Banerjee A, Leary S, Crotty E, Abdelbaki M, Whipple N, Goldman S, Margol A, Bhatia A, Dababo N, George E, Nabavizadeh A, Pampaloni MH, Inagaki A, Collins S, Chuntova P, Barcova M, Patel TS, Phillips J, Prados M, Molinaro A, Gupta N, Raffel C, Cole K, Kasahara N, Diaz AA, Mueller S
Publication
Clinical cancer research : an official journal of the American Association for Cancer Research
Publication ID (Profile URL)
https://researcherprofiles.org/profile/642809391
Publication Year
2025
PubMed ID
40540301
Publication Title
Yu B, Kline C, Hoare O, Jung J, Knowles T, Ranavaya A, Minturn J, Banerjee A, Leary S, Crotty E, Abdelbaki M, Whipple N, Goldman S, Margol A, Bhatia A, Dababo N, George E, Nabavizadeh A, Pampaloni MH, Inagaki A, Collins S, Chuntova P, Barcova M, Patel TS, Phillips J, Prados M, Molinaro A, Gupta N, Raffel C, Cole K, Kasahara N, Diaz AA, Mueller S. Measles Oncolytic Virus as an Immunotherapy for Recurrent/Refractory Pediatric Medulloblastoma and Atypical Teratoid/Rhabdoid Tumor: Results from PNOC005. Clin Cancer Res. 2025 Aug 14; 31(16):3463-3475.
Publication Medline TA
Clin Cancer Res
Date
2025-08-14